Evidence map›Paper›PMID 29099289›Full record

ArticleEpigenetics2017

Trichostatin A decreases the levels of MeCP2 expression and phosphorylation and increases its chromatin binding affinity.

Katrina V Good, Alexia Martínez de Paz, Monica Tyagi, Manjinder S Cheema, Anita A Thambirajah, Taylor L Gretzinger, Gilda Stefanelli, Robert L Chow, Oliver Krupke, Michael Hendzel and 4 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Epigenetics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Dual mechanisms for the regulation of brain-derived neurotrophic factor by valproic acid in neural progenitor cells.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Katrina V Gooda Department of Biochemistry and Microbiology , University of Victoria , Victoria , BC , V8W 3P6 , Canada.
Alexia Martínez de Paza Department of Biochemistry and Microbiology , University of Victoria , Victoria , BC , V8W 3P6 , Canada.
Monica Tyagia Department of Biochemistry and Microbiology , University of Victoria , Victoria , BC , V8W 3P6 , Canada.
Manjinder S Cheemaa Department of Biochemistry and Microbiology , University of Victoria , Victoria , BC , V8W 3P6 , Canada.
Anita A Thambirajaha Department of Biochemistry and Microbiology , University of Victoria , Victoria , BC , V8W 3P6 , Canada.
Taylor L Gretzingera Department of Biochemistry and Microbiology , University of Victoria , Victoria , BC , V8W 3P6 , Canada.
Gilda Stefanellic Department of Medical Biotechnology and Translational Medicine , University of Milan , Milan , Italy.
Robert L Chowd Department of Biology , University of Victoria , Victoria , BC , V8W 3P6 , Canada.
Oliver Krupked Department of Biology , University of Victoria , Victoria , BC , V8W 3P6 , Canada.
Michael Hendzele Department of Cell Biology , Faculty of Medicine and Dentistry , University of Alberta , Edmonton , Alberta , Canada.
Kristal Missiaenf Department of Oncology and Department of Cell Biology , Faculty of Medicine and Dentistry , University of Alberta , Edmonton , Alberta , Canada.
Alan Underhillf Department of Oncology and Department of Cell Biology , Faculty of Medicine and Dentistry , University of Alberta , Edmonton , Alberta , Canada.
Nicoletta Landsbergerc Department of Medical Biotechnology and Translational Medicine , University of Milan , Milan , Italy.
Juan Ausióa Department of Biochemistry and Microbiology , University of Victoria , Victoria , BC , V8W 3P6 , Canada.
University of Victoria · CAUniversity of Alberta · CAUniversity of Milan · ITMcGill University · CA

Funding

CIHR MOP -130417
6 · The paper itself

Abstract

MeCP2 binds to methylated DNA in a chromatin context and has an important role in cancer and brain development and function. Histone deacetylase (HDAC) inhibitors are currently being used to palliate many cancer and neurological disorders. Yet, the molecular mechanisms involved are not well known for the most part and, in particular, the relationship between histone acetylation and MeCP2 is not well understood. In this paper, we study the effect of the HDAC inhibitor trichostatin A (TSA) on MeCP2, a protein whose dysregulation plays an important role in these diseases. We find that treatment of cells with TSA decreases the phosphorylation state of this protein and appears to result in a higher MeCP2 chromatin binding affinity. Yet, the binding dynamics with which the protein binds to DNA appear not to be significantly affected despite the chromatin reorganization resulting from the high levels of acetylation. HDAC inhibition also results in an overall decrease in MeCP2 levels of different cell lines. Moreover, we show that miR132 increases upon TSA treatment, and is one of the players involved in the observed downregulation of MeCP2.

Indexed as

3T3 CellsAnimalsChromatinHEK293 CellsHeLa CellsHistone Deacetylase InhibitorsHumansHydroxamic AcidsMethyl-CpG-Binding Protein 2MicePhosphorylationProtein BindingProtein Processing, Post-TranslationalChromatinHistone Deacetylase InhibitorsHydroxamic AcidsMECP2 protein, humanMethyl-CpG-Binding Protein 2trichostatin Achromatinhistone acetylationMeCP2miR-132Trichostatin A (TSA)

Identifiers

PMID29099289
PMCPMC5788420
OpenAlexW2766363568

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.